Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: huntington disease

January 15, 2024 CD as API / Drug delivery / Pharma applications

Towards Understanding Neurodegenerative Diseases: Insights from Caenorhabditis elegans

The elevated occurrence of debilitating neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), Alzheimer’s disease (AD), Parkinson’s

Continue reading

August 30, 2023 CD derivatives / Drug delivery / Pharma applications

Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin

Huntington’s disease (HD) is a progressive inherited neurodegenerative disease caused by a CAG repeat expansion in the huntingtin gene, which

Continue reading

February 16, 2023 Drug delivery / Pharma applications

Nanotherapeutic and Stem Cell Therapeutic Strategies in Neurodegenerative Diseases: A Promising Therapeutic Approach

Neurodegeneration is characterized by progressive, disabling, and incurable neurological disorders with the massive loss of specific neurons. As one of

Continue reading

February 4, 2021 CD as API / Drug delivery / Events

Press Release – Development of Autophagy Inducing Cyclodextrin Derivatives for Aging-associated Diseases

CycloLab Cyclodextrin R&D Ltd. proudly announces winning of a national grant about the development of cyclodextrin-dervatives for autophagy-associated neurodegenerative diseases.

Continue reading

Recent Posts

  • Special issue: Advanced Polymeric Biomaterials for Drug Delivery Applications
  • On-off switch of cellular migration using granular hydrogels containing beta-CD and adamantane
  • Nitric Oxide-Releasing Thixotropic Hydrogels as Antibacterial and Hemocompatible Catheter Locks
  • delta-Cyclodextrin is commercially available at Biosynth
  • Beren Therapeutics’Adrabetadex Received FDA Acceptance for infantile-onset Niemann Pick Disease

Tags

alpha-CD Alzheimer disease atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (26)
  • Analysis (63)
  • CD as API (333)
  • CD derivatives (384)
  • Cosmetics and toilettry (49)
  • Diagnosis (11)
  • Drug delivery (764)
  • E-ducation (63)
  • Environmental (128)
  • Events (231)
  • Food (215)
  • Gene delivery (19)
  • Household products (4)
  • Household products (1)
  • In Hungarian (4)
  • Life sciences (41)
  • Non-pharma applications (385)
  • Other industrial use (102)
  • Pharma applications (1,143)
  • Supramolecular systems (39)
  • Uncategorized (140)

Top Posts

  • On-off switch of cellular migration using granular hydrogels containing beta-CD and adamantane
  • delta-Cyclodextrin is commercially available at Biosynth
  • Special issue: Advanced Polymeric Biomaterials for Drug Delivery Applications
  • New FDA approved medicinal product containing Betadex sulfobutylether sodium: VYKOURA
  • 5th International Conference Integrative Chemistry, Biology & Translational Medicine
  • Website registration and abstract submission for 21st International Cyclodextrin Symposium open
  • Effect of CD on the antiaging drug: rapamycin
  • Enhancing the Water Solubility and Efficacy of Anticancer Drugs Using Hydroxypropyl-β-Cyclodextrin
  • CD-MOF in cosmetics: Noble Panacea products from Nobel Laureate Sir Fraser Stoddart
  • Australian company pioneering Cavadextrin for regression of atherosclerosis

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 3,792 other subscribers
 

Loading Comments...